Novartis will continue to provide supply of HCQ for ongoing investigator-initiated trials (IITs) and upon government requests, as appropriate, where certain conditions are met and the medicine is used ...
Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.
Report a suspected side effect related to Novartis product here.
Strong values define our culture and help us execute the Novartis strategy in line with our mission and vision. We have introduced Values and Behaviors that describe the professional behaviors we ...
Novartis aims to tackle breast cancer with bold science, collaboration, and a passion for transforming patient care. We take a bold approach to our research by including patient populations who are ...
“The language that is used when speaking with a patient is probably one of the most important things about being diagnosed – and that language, I think, has to change.” Leanne Pero, ex-dance teacher, ...
At Novartis, we don’t just discover life-changing medicines, we're part of a broader effort to help ensure medicines reach the people who need them most, wherever they live, because the true value of ...
Basel, August 8, 2024 – Novartis today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta ® (iptacopan), a first-in-class complement inhibitor for ...
Disclaimer: This investor update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally ...
Novartis signs agreement to divest ‘front of eye’ ophthalmology assets in line with focused strategy
Divested assets to include Xiidra ®, on-market treatment for dry eye disease and SAF312 (libvatrep), potential therapy for chronic ocular surface pain Deal consistent with Novartis focused strategy of ...
Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction ...
HS is a chronic, inflammatory skin condition affecting up to one in 100 people worldwide 2, resulting in painful, potentially disfiguring lesions, which leaves feelings of stigmatization and can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback